<?xml version="1.0" encoding="UTF-8"?>
<p>Akhtar et al. synthesised BTA and 1,3,4-oxadiazole-2-thione derivatives and determined their antitumor potential in 
 <italic>in-vitro</italic> against different tumour cell lines. BTA derivatives 
 <bold>19</bold> (N-(benzo[d]thiazol-2-yl)-2–(5-(1–(2-chlorophenoxy)propyl)-1,3,4-oxadiazol-2-ylthio)acetamide) and 
 <bold>20</bold> (N-(benzo[d]thiazol-2-yl)-2–(5-(1–(3,4-dichlorophenoxy)ethyl)-1,3,4-oxadiazol-2-ylthio) acetamide) exhibited remarkable activities against CCRF-CEM (leukaemia) cell lines. The CC
 <sub>50</sub> values of compounds 
 <bold>19</bold> and 
 <bold>20</bold> (CC
 <sub>50</sub> = 12 
 <inline-formula id="ilm0002">
  <alternatives>
   <inline-graphic xlink:href="IENZ_A_1698036_ILM0002.jpg" xmlns:xlink="http://www.w3.org/1999/xlink"/>
   <math id="d2e754">
    <mo>±</mo>
   </math>
  </alternatives>
 </inline-formula> 2 µM and 8 
 <inline-formula id="ilm0003">
  <alternatives>
   <inline-graphic xlink:href="IENZ_A_1698036_ILM0003.jpg" xmlns:xlink="http://www.w3.org/1999/xlink"/>
   <math id="d2e760">
    <mo>±</mo>
   </math>
  </alternatives>
 </inline-formula> 1 µM respectively) were comparable to the standard drug Doxorubicin. The replacement of the chloro moiety with bromo in the hybrid structures of 
 <bold>19</bold> and 
 <bold>20</bold> decreased their anti-tumour potential (
 <xref ref-type="fig" rid="F0012">Figure 12</xref>)
 <xref rid="CIT0032" ref-type="bibr">
  <sup>32</sup>
 </xref>.
</p>
